心臟再同步治療市場規模、佔有率、成長分析、按產品、按應用、按最終用戶、按地區 - 產業預測，2024-2031年

2022年全球心臟再同步治療市場規模價值為41億美元，預計從2023年的42.9億美元成長到2031年的61.5億美元，在預測期內（2024-2031年）年複合成長率為4.6%。

由於目標疾病盛行率上升、心臟病盛行率急劇上升、治療投資增加以及醫療保健支出增加，心臟再同步治療市場預計將成長。此外，技術進步、醫療設備現代化、新興市場擴張以及老年人口的增加進一步推動了市場成長。然而，不利的醫療改革、手術部位感染風險增加以及設備敏感性增加等挑戰可能會限制這種成長，並且是預測期內需要解決的障礙。了解這些動態對於尋求駕馭不斷變化的市場格局的相關人員非常重要。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二級資料和一級資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 依細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2023）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析

依產品分類的心臟再同步治療市場規模及年複合成長率（2024-2031）

• 市場概況
• 心臟再同步治療心臟去顫器
• 心臟再同步治療心律調節器

依應用分類的心臟再同步治療市場規模和年複合成長率（2024-2031）

• 市場概況
• 室間不同步
• 室間（V-V）不同步
• 房室（A-V）不同步

依最終用戶分類的心臟再同步治療市場規模和年複合成長率（2024-2031）

• 市場概況
• 醫院和心臟中心
• 門診手術中心
• 其他

心臟再同步治療市場規模及年複合成長率（2024-2031）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東、非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東、非洲

競爭資訊

• 前5名企業比較
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2023）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 依細分市場分類的佔有率分析
  • 收益與前一年同期比較（2021-2023）

主要企業簡介

• Medtronic plc（Ireland）
• Boston Scientific Corporation（USA）
• Abbott Laboratories（USA）
• BIOTRONIK SE & Co. KG（Germany）
• Lepu Medical Technology Co., Ltd.（China）
• MicroPort Scientific Corporation（China）
• LivaNova PLC（UK）
• Medico SpA（Italy）
• Nihon Kohden Corporation（Japan）
• Koninklijke Philips NV（Netherlands）
• Japan Lifeline Co., Ltd.（Japan）
• Shree Pacetronix Ltd.（India）
• Integer Holdings Corporation（OSCOR Inc.）（USA）
• Osypka Medical GmbH（Germany）
• St. Jude Medical, Inc.（acquired by Abbott）（USA）
• Accellent Inc.（USA）
• Cameron Health（acquired by Emerson Electric Co.）（USA）
• Sorin Group（acquired by LivaNova）（Italy）
• Guidant Corporation（acquired by Boston Scientific）（USA）
• Cyberonics, Inc.（acquired by Abbott）（USA）

結論和建議

Global Cardiac Resynchronization Therapy Market size was valued at USD 4.1 billion in 2022 and is poised to grow from USD 4.29 billion in 2023 to USD 6.15 billion by 2031, growing at a CAGR of 4.6% during the forecast period (2024-2031).

The cardiac resynchronization therapy market is poised for growth, driven by a rising incidence of target diseases, a surge in heart attack prevalence, increased investment in treatment, and growing healthcare expenditures. Additionally, advancements in technology, modernization of medical equipment, expansion into emerging markets, and a growing geriatric population will further propel market growth. However, challenges such as unfavorable healthcare reforms, heightened risks of surgical site infections, and high sensitivity of devices could restrain this growth, presenting hurdles that need to be addressed during the forecast period. Understanding these dynamics will be crucial for stakeholders looking to navigate the evolving landscape of the cardiac resynchronization therapy market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cardiac Resynchronization Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cardiac Resynchronization Therapy Market Segmental Analysis

Global Cardiac Resynchronization Therapy Market is segmented by product, application, end user and region. Based on product, the market is segmented into cardiac resynchronization therapy defibrillators and cardiac resynchronization therapy pacemakers. Based on application, the market is segmented into intraventricular desynchrony, interventricular (V-V) desynchrony and atrioventricular (A-V) desynchrony. Based on end user, the market is segmented into hospitals & cardiac centers, ambulatory surgery centers and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cardiac Resynchronization Therapy Market

The Global Cardiac Resynchronization Therapy market is significantly driven by the escalating prevalence of cardiovascular diseases, which continue to pose a serious health challenge worldwide. Sudden cardiac death accounts for nearly half of all fatalities linked to cardiovascular conditions, underscoring the urgent need for effective interventions. Despite advancements in treatment options, the incidence of heart diseases and associated risk factors is on the rise, leading to an increased demand for cardiac resynchronization therapy devices. With heart failure being one of the primary causes of mortality globally, the necessity for innovative therapies is more critical than ever, prompting growth in this market.

Restraints in the Global Cardiac Resynchronization Therapy Market

A significant restraint in the Global Cardiac Resynchronization Therapy market is the issue of product recalls, which can affect consumer confidence and market growth. For example, Boston Scientific Corporation initiated a recall of its INGENIO family of pacemakers and CRT-Ps in June 2022, which included models like the ADVANTIO DR EL, INGENIO DR EL, and VITALIO DR EL. These devices were distributed in the U.S. between November 2016 and August 2022, having been manufactured from September 2016 to December 2018, totaling around 48,000 units. The recall was prompted by concerns that the devices could inadvertently enter safety mode, posing risks to patients' well-being.

Market Trends of the Global Cardiac Resynchronization Therapy Market

The Global Cardiac Resynchronization Therapy (CRT) market is currently experiencing significant growth driven by the rising prevalence of cardiovascular diseases and the need for effective heart failure management. CRT-Defibrillators (CRT-D), which not only promote synchronized heart contractions but also address life-threatening arrhythmias, are becoming increasingly vital in patient treatment strategies. Innovations such as smartphone connectivity and integrated applications are enhancing patient engagement and enabling remote monitoring, further augmenting their appeal. Additionally, advancements in device design, including improved battery life and MRI compatibility, are positioning CRT-D devices as critical tools in modern cardiology, reflecting a robust upward trend in this market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Cardiac Resynchronization Therapy Market Size by Product & CAGR (2024-2031)

• Market Overview
• Cardiac Resynchronization Therapy Defibrillators
• Cardiac Resynchronization Therapy Pacemakers

Global Cardiac Resynchronization Therapy Market Size by Application & CAGR (2024-2031)

• Market Overview
• Intraventricular Desynchrony
• Interventricular (V-V) Desynchrony
• Atrioventricular (A-V) Desynchrony

Global Cardiac Resynchronization Therapy Market Size by End User & CAGR (2024-2031)

• Market Overview
• Hospitals & Cardiac Centers
• Ambulatory Surgery Centers
• Others

Global Cardiac Resynchronization Therapy Market Size & CAGR (2024-2031)

• North America (Product, Application, End User)
  • US
  • Canada
• Europe (Product, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BIOTRONIK SE & Co. KG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lepu Medical Technology Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MicroPort Scientific Corporation (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LivaNova PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medico S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nihon Kohden Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Koninklijke Philips N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Japan Lifeline Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shree Pacetronix Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Integer Holdings Corporation (OSCOR Inc.) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Osypka Medical GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• St. Jude Medical, Inc. (acquired by Abbott) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Accellent Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cameron Health (acquired by Emerson Electric Co.) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sorin Group (acquired by LivaNova) (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guidant Corporation (acquired by Boston Scientific) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cyberonics, Inc. (acquired by Abbott) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations